Gregory Alan Korbel - Dec 1, 2021 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role
SVP, Chief Business Officer
Signature
/s/ Scott M. Coiante, attorney-in-fact
Stock symbol
APRE
Transactions as of
Dec 1, 2021
Transactions value $
-$83,600
Form type
4
Date filed
12/3/2021, 04:01 PM
Previous filing
Nov 3, 2021
Next filing
Mar 1, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APRE Common Stock Options Exercise $25.3K +27.5K +160.19% $0.92* 44.7K Dec 1, 2021 Direct
transaction APRE Common Stock Sale -$109K -27.5K -61.57% $3.96 17.2K Dec 1, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APRE Stock Option (right to Buy) Options Exercise $0 -27.5K -92.17% $0.00 2.34K Dec 1, 2021 Common Stock 27.5K $0.92 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.81 to $4.12 inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 This option was granted on February 26, 2017 and is fully exercisable.